Benchmark Reiterates Buy on Bio-Techne, Maintains $95 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman has reiterated a Buy rating on Bio-Techne (NASDAQ:TECH) and maintained a $95 price target.
August 13, 2024 | 2:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman has reiterated a Buy rating on Bio-Techne (NASDAQ:TECH) and maintained a $95 price target.
The reiteration of a Buy rating and the maintenance of a $95 price target by a reputable analyst is likely to positively impact Bio-Techne's stock price in the short term. This indicates continued confidence in the company's performance and potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100